HDAC2 as a new target to improve schizophrenia treatment

about

Epigenetic Mechanisms of Serotonin Signaling.Epigenetic signaling in schizophrenia Differences in 5-HT2A and mGlu2 Receptor Expression Levels and Repressive Epigenetic Modifications at the 5-HT2A Promoter Region in the Roman Low- (RLA-I) and High- (RHA-I) Avoidance Rat Strains.

P2860

Q27027985-17E7099E-7777-4DD9-AF39-2129047E09AB Q34482708-0E4CC117-6D34-47C7-84C2-9D02489C3566 Q45054111-1D0143D4-E875-4962-B10E-711766FF414F

P2860

HDAC2 as a new target to improve schizophrenia treatment

Item

http://www.wikidata.org/entity/Q41989010

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

HDAC2 as a new target to improve schizophrenia treatment

@en

type

Item

label

HDAC2 as a new target to improve schizophrenia treatment

@en

prefLabel

HDAC2 as a new target to improve schizophrenia treatment

@en

P1476

HDAC2 as a new target to improve schizophrenia treatment

@en

P2093

Javier González-Maeso

http://www.w3.org/2001/XMLSchema#string

Mitsumasa Kurita

http://www.w3.org/2001/XMLSchema#string

Terrell Holloway

http://www.w3.org/2001/XMLSchema#string

P2860

Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA demethylation

Identification of a serotonin/glutamate receptor complex implicated in psychosis

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior

HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity.

Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone.

Augmentation of atypical antipsychotics with valproic acid. An open-label study for most difficult patients with schizophrenia.

Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia.

Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs.

Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.

P304

1-3

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1586/ERN.12.141

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233956951

http://www.w3.org/2001/XMLSchema#string

P698

23253383

http://www.w3.org/2001/XMLSchema#string

P921

schizophrenia

P932

3552246

http://www.w3.org/2001/XMLSchema#string

HDAC2 as a new target to improve schizophrenia treatment

about

P2860

P2860

HDAC2 as a new target to improve schizophrenia treatment

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P921

P932